...
首页> 外文期刊>Pathology oncology research: POR >Comparison of the Amplification Refractory Mutation System, Super Amplification Refractory Mutation System, and Droplet Digital PCR for T790?M Mutation Detection in Non-small Cell Lung Cancer after Failure of Tyrosine Kinase Inhibitor Treatment
【24h】

Comparison of the Amplification Refractory Mutation System, Super Amplification Refractory Mutation System, and Droplet Digital PCR for T790?M Mutation Detection in Non-small Cell Lung Cancer after Failure of Tyrosine Kinase Inhibitor Treatment

机译:酪氨酸激酶抑制剂失败后,在非小细胞肺癌中进行扩增耐火突变体系,超扩增耐火突变体系和液滴数量PCR的比较

获取原文
获取原文并翻译 | 示例
           

摘要

Plasma mutation detection has the advantages of non-invasiveness and accessibility. Here, we evaluated three methods, the amplification refractory mutation system (ARMS), second-generation ARMS (SuperARMS), and droplet digital PCR (ddPCR), to assess their concordance and feasibility for the detection of mutations in plasma samples. Non-small lung cancer patients with stage IIIB/IV that were resistant to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment were enrolled. Blood samples were collected within 14?days after TKI resistance. Each sample was simultaneously assessed by the three methods. In total, 169 patients were enrolled; 54.4% were female, 72.2% were diagnosed with stage IV disease; and 97.6% had adenocarcinoma. T790?M mutations were detected in 42 (24.8%) of the 169 samples using ARMS, one of which carried the T790?M alone, 22 that also encoded exon 19 deletions, and 19 with L858R mutations. For the SuperARMS assay, 59 (34.9%) samples exhibited the T790?M mutation, and 110 (65.1%) showed no detectable T790?M mutation. ddPCR showed that 61 (36.1%) samples contained the T790?M mutation, whereas 108 (63.9%) were not positive. T790?M abundance ranged from 0.04% to 38.2%. The median T790?M abundance was 0.15% for total samples and 2.98% for T790?M mutation samples. The overall concordance was 78.7% (133/169) among ARMS, SuperARMS, and ddPCR. Compared with patients with stage III disease, patients with stage IV disease exhibited a higher T790?M mutation detection rate (28.7% vs. 14.9% by ARMS; 37.7% vs. 27.7% by SuperARMS; and 41.8% vs. 21.3% by ddPCR). Liquid biopsy showed promise and has the advantages of non-invasiveness and accessibility. T790?M detection based on circulating tumor DNA showed high concordance. Compared with non-digital platforms, ddPCR showed higher sensitivity and provided both frequency and abundance information, which might be important for treatment decisions.
机译:等离子体突变检测具有非侵入性和可访问性的优点。这里,我们评估了三种方法,扩增耐火突变系统(臂),第二代臂(超领域)和液滴数量PCR(DDPCR),以评估它们在血浆样品中检测突变的一致性和可行性。注册了患有表皮生长因子受体 - 酪氨酸激酶抑制剂(EGFR-TKI)治疗的阶段IIIB / IV的非小肺癌患者。在TKI抗性后14.在14-天内收集血样。通过三种方法同时评估每个样品。共有169名患者; 54.4%是女性,72.2%被诊断为阶段IV疾病; 97.6%有腺癌。使用臂中的一种在169个样品的42(24.8%)中检测T790突变,其中一个单独携带T790〜M,22,22,其编码外显子19缺失,19例具有L858R突变。对于Superarms测定,59(34.9%)样品表现出T790?M突变,110(65.1%)显示出没有可检测的T790?M突变。 DDPCR显示61(36.1%)样品含有T790突变,而108(63.9%)不是阳性的。 T790?M丰度范围从0.04%到38.2%。总样品的中位数T790?M丰度为0.15%,对于T790突变样品,2.98%。整体一致性是78.7%(133/169)在武器,超级渣和DDPCR之间。与III阶段疾病患者相比,IV阶段疾病的患者表现出更高的T790?M突变检测率(由武器28.7%与14.9%; 37.7%vs.27.7%,由Superarms; DDPCR 41.8%与21.3% )。液体活检显示了承诺,具有非侵入性和可访问性的优点。基于循环肿瘤DNA的T790ΔM检测显示高一致性。与非数字平台相比,DDPCR显示出更高的灵敏度,并提供频率和丰度信息,这对于治疗决策可能是重要的。

著录项

  • 来源
    《Pathology oncology research: POR》 |2018年第4期|共9页
  • 作者单位

    Department of Oncology Hangzhou First People’s Hospital Nanjing Medical University;

    Hangzhou Translational Medicine Research Center Hangzhou First People’s Hospital Nanjing Medical;

    Hangzhou Translational Medicine Research Center Hangzhou First People’s Hospital Nanjing Medical;

    Hangzhou Translational Medicine Research Center Hangzhou First People’s Hospital Nanjing Medical;

    Department of Oncology Hangzhou Cancer Hospital;

    Department of Oncology Hangzhou First People’s Hospital Nanjing Medical University;

    Department of Respiratory Hangzhou First People’s Hospital Nanjing Medical University;

    Department of Thoracic Surgery Hangzhou First People’s Hospital Nanjing Medical University;

    Hangzhou First People’s Hospital Nanjing Medical University;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 病理学;
  • 关键词

    T790?M; ctDNA; ARMS; ddPCR; SuperARMS; TKI resistance;

    机译:t790?m;ctdna;武器;ddpcr;superarms;tki抵抗;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号